Artificial Intelligence With Deep Learning and Genes on Cardiovascular Disease
NCT ID: NCT03877614
Last Updated: 2019-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
5000 participants
OBSERVATIONAL
2018-08-28
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young Adults
NCT02496858
Self-Scored Cardiovascular Disease Risk Appraisal
NCT00005529
Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study
NCT00262691
Risk Factors of Individuals With Coronary Artery Disease
NCT00260104
A Case-control Study to Assess the Association Between Facial Characteristics and Coronary Artery Diseases
NCT03214783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will analyze the differences in the individualization of cardiovascular disease between diseases and other subjects to further improve the quality of care for clinical patients. By using artificial intelligence deep learning system, the investigators hope to not only improve the diagnostic rate and also gain more accurately predict the patient's recovery, improve medical quality in the near future.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cardiovascular high-risk (disease) group
A. Coronary artery disease B. Congestive heart failure with reduced ejection fraction C. Hypertrophic cardiomyopathy D. Atrial fibrillation E. Pulmonary hypertension F. Fabry's disease
ASCVD risk score
ASCVD score\< 10% will be in the control or low-risk group
Cardiovascular Low-risk (control) group
Patient with only risk factors with ASCVD score\<10% will be recognized as the comparison group
ASCVD risk score
ASCVD score\< 10% will be in the control or low-risk group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ASCVD risk score
ASCVD score\< 10% will be in the control or low-risk group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
We will enroll subjects from either cardiovascular clinics or inpatients from the National Cheng Kung University Hospital from 2018 to 2021 after the signature of inform consent from patients and their families. The major enrollment criteria include one of the flowing diseases or conditions:
A. Coronary artery disease:
1. History of myocardial infarction
2. Coronary artery disease with computer tomography angiography image study with at least one vessel luminal stenosis \>70%
3. Coronary artery stents implantation by hospital-based image database
4. Thallium-201 scan positive/treadmill test positive with additional 2 risk factors, including
1. Diabetes mellitus
2. Hypertension
3. Dyslipidemia
4. Family history of sudden death, coronary bypass surgery, cerebral vascular attacks (CVA), premature myocardial infarction
5. Smoking behaviors
B. Congestive heart failure with reduced ejection fraction
1\. Echocardiography left ventricular ejection fraction \<40%
C. Hypertrophic cardiomyopathy:
1. Left ventricle interventricular septum(IVS) \>15 mm
2. Left ventricle mass index\> 200gm
3. Apical hypertrophy noted on the report with 4 chamber view
D. Atrial fibrillation
1. Recorded by Holter continuous EKG
2. Recorded by standard 12 leads complete EKG
E. Pulmonary hypertension
1. Echo with systolic pulmonary pressure (sysPAP)\> 40 mmHg
2. Diagnosis of idiopathic pulmonary hypertension
3. Under pulmonary hypertension medication
F. Fabry's disease
1. α-Galactosidase (a-GAL) enzyme deficiency
2. Genetic disorder
G. Patient with only risk factors (\<3 risk factors), recognized as the comparison group (\>500 cases)
1. Diabetes mellitus
2. Hypertension
3. Dyslipidemia
4. Family history of sudden death, coronary bypass surgery, cerebral vascular attacks, premature myocardial infarction
5. Smoking behavior
Exclusion Criteria
* Concentration of DNA collection was inadequate after 3 times of collection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cheng-Kung University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ping-Yen Liu
Director of Cardiology, Internal Medicine and Professor of Institute of Clinical Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Internal Medicine, National Cheng Kung University Hospital
Tainan City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Hsu YL, Huang MS, Chang HY, Lee CH, Chen DP, Li YH, Chao TH, Liu YW, Liu PY. Application of genetic risk score for in-stent restenosis of second- and third-generation drug-eluting stents in geriatric patients. BMC Geriatr. 2023 Jul 19;23(1):443. doi: 10.1186/s12877-023-04103-w.
Lee PT, Huang MH, Huang TC, Hsu CH, Lin SH, Liu PY. High Burden of Premature Ventricular Complex Increases the Risk of New-Onset Atrial Fibrillation. J Am Heart Assoc. 2023 Feb 21;12(4):e027674. doi: 10.1161/JAHA.122.027674. Epub 2023 Feb 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-ER-107-149
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.